Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease

被引:5
|
作者
Alexopoulos, Panagiotis [1 ,2 ]
Roesler, Jennifer [2 ]
Werle, Lukas [2 ,3 ]
Thierjung, Nathalie [2 ]
Lentzari, Iliana [1 ]
Ortner, Marion [2 ]
Grimmer, Timo [2 ]
Laskaris, Nikolaos [4 ]
Politis, Antonios [5 ,6 ]
Gourzis, Philippos [1 ]
Kurz, Alexander [2 ]
Perneczky, Robert [7 ,8 ,9 ,10 ]
机构
[1] Univ Patras, Dept Psychiat, Rion 26500, Greece
[2] Tech Univ Munich, Dept Psychiat & Psychotherapy, Ismaninger Str 22, D-81675 Munich, Germany
[3] Max Planck Inst Psychiat, Munich, Germany
[4] Aristotle Univ Thessaloniki, Dept Informat, Thessaloniki 54124, Greece
[5] Univ Athens, Eginit Hosp, Dept Psychiat 1, Vassilissis Sofias Ave 72-74, Athens 11528, Greece
[6] Johns Hopkins Med Sch, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Baltimore, MD USA
[7] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany
[8] Imperial Coll Sci Technol & Med, Sch Publ Hlth, Neuroepidemiol & Ageing Res Unit, Fac Med, London, England
[9] West London Mental Hlth NHS Trust, London, England
[10] German Ctr Neurodegenerat Dis DZNE Munich, Munich, Germany
基金
加拿大健康研究院; 美国国家卫生研究院;
关键词
beta-Amyloid; 1-42; Total tau; Phosphorylated tau 181; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; APOLIPOPROTEIN-E; CSF BIOMARKERS; AMYLOID-BETA; DIAGNOSTIC EVALUATION; TAU PATHOLOGY; RECOMMENDATIONS; DECLINE; MARKERS;
D O I
10.1007/s00702-017-1810-z
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The cerebrospinal fluid (CSF) levels of beta-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N = 119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy). The statistical analyses relied on distance correlation analysis and kappa (k) statistics. Poor agreement (k < 0.4) and low interrelations between the studied biomarkers were detected in all cases with the exception of the interrelation between the markers total tau and phosphorylated tau 181, especially in the monocentric sample. Interestingly, lower interrelation and agreement degrees were observed in carriers of the Apolipoprotein E epsilon 4 allele compared to non-carriers. The clinical phenotype currently referred to as "AD dementia" is characterized by an inhomogeneous CSF biomarker profile, possibly mirroring the complex genesis of AD-typical dementia symptoms and pointing to the necessity of shedding more light on the hypothesis of biomarker stability over time in symptomatic AD.
引用
收藏
页码:193 / 201
页数:9
相关论文
共 50 条
  • [41] Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia
    Chiu, Pai-Yi
    Yang, Fu-Chi
    Chiu, Ming-Jang
    Lin, Wei-Che
    Lu, Cheng-Hsien
    Yang, Shieh-Yueh
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [42] Folate and Homocysteine in the Cerebrospinal Fluid of Patients with Alzheimer's Disease or Dementia: A Case Control Study
    Smach, Mohamed Ali
    Jacob, Nelly
    Golmard, Jean-Louis
    Charfeddine, Bassem
    Lammouchi, Turkia
    Ben Othman, Leila
    Dridi, Hedi
    Bennamou, Soufien
    Limem, Khalifa
    EUROPEAN NEUROLOGY, 2011, 65 (05) : 270 - 278
  • [43] Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia
    Ezzati, Ali
    Abdulkadir, Ahmed
    Jack, Clifford R., Jr.
    Thompson, Paul M.
    Harvey, Danielle J.
    Truelove-Hill, Monica
    Sreepada, Lasya P.
    Davatzikos, Christos
    Lipton, Richard B.
    ALZHEIMERS & DEMENTIA, 2021, 17 (11) : 1855 - 1867
  • [44] Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic
    Stiffel, Michael
    Bergeron, David
    Amari, Karim Mourabit
    Poulin, Elizabeth
    Roberge, Xavier
    Meilleur-Durand, Synthia
    Sellami, Leila
    Molin, Pierre
    Nadeau, Yannick
    Fortin, Marie-Pierre
    Caron, Stephanie
    Poulin, Stephane
    Verret, Louis
    Bouchard, Remi W.
    Teunissen, Charlotte
    Laforce, Robert, Jr.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2022, 49 (02) : 203 - 209
  • [45] Using Cerebrospinal Fluid Marker Profiles in Clinical Diagnosis of Dementia with Lewy Bodies, Parkinson's Disease, and Alzheimer's Disease
    Kaerst, Lisa
    Kuhlmann, Andre
    Wedekind, Dirk
    Stoeck, Katharina
    Lange, Peter
    Zerr, Inga
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 38 (01) : 63 - 73
  • [46] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
    Zetterberg, Henrik
    Blennow, Kaj
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 : S361 - S369
  • [47] Clinical use of cerebrospinal fluid biomarkers in Alzheimer's disease
    Zetterberg, Henrik
    Lunn, Michael P.
    Herukka, Sanna-Kaisa
    BIOMARKERS IN MEDICINE, 2012, 6 (04) : 371 - 376
  • [48] The Impact of Cerebrospinal Fluid Biomarkers on the Diagnosis of Alzheimer's Disease
    Engelborghs, Sebastiaan
    Le Bastardl, Nathalie
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (03) : 135 - 141
  • [49] Evaluation of annexin A5 as a biomarker for Alzheimer's disease and dementia with lewy bodies
    Sohma, Hitoshi
    Imai, Shin-ichi
    Takei, Norio
    Honda, Hirohito
    Matsumoto, Kyoichi
    Utsumi, Kumiko
    Matsuki, Kayo
    Hashimoto, Eri
    Saito, Toshikazu
    Kokai, Yasuo
    FRONTIERS IN AGING NEUROSCIENCE, 2013, 5
  • [50] Differential Functional Connectivity Correlates of Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer's Type
    Malpas, Charles B.
    Saling, Michael M.
    Velakoulis, Dennis
    Desmond, Patricia
    O'Brien, Terence J.
    NEURODEGENERATIVE DISEASES, 2016, 16 (3-4) : 147 - 151